Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3Breast 3Gynecologic 2Gastrointestinal 2Genitourinary 1

Conditions

Breast Neoplasms 326Neoplasm Metastasis 40Neoplasms 25Ovarian Neoplasms 18Advanced Breast Cancer 18Carcinoma, Non-Small-Cell Lung 14Endometrial Neoplasms 11Prostatic Neoplasms 10Hereditary Sensory and Autonomic Neuropathies 10Triple Negative Breast Neoplasms 8Colorectal Neoplasms 6Breast Cancer Metastatic 6Uterine Cervical Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Recurrence 5Multiple Endocrine Neoplasia Type 1 5Carcinoma, Ovarian Epithelial 5Breast Diseases 5Neoplasms by Site 4Stomach Neoplasms 3Small Cell Lung Carcinoma 3Lung Neoplasms 3Head and Neck Neoplasms 3Fallopian Tube Neoplasms 3Carcinoma, Lobular 3Breast Neoplasm Female 3Uterine Neoplasms 2Pancreatic Neoplasms 2Melanoma 2Lymphoma, Non-Hodgkin 2

Interventions

Etoposide 155Carboplatin 144Cisplatin 105Topotecan 76durvalumab 52atezolizumab 50Irinotecan 45pembrolizumab 38Paclitaxel 34Nivolumab 33Radiotherapy 31PM 01183 24Drug Therapy 24anlotinib 23Gemcitabine 21apatinib 19Ipilimumab 18Docetaxel 17Temozolomide 16Platinum 16Radiosurgery 15Pemetrexed 14toripalimab 13tislelizumab 13olaparib 13Magnetic Resonance Spectroscopy 13Bevacizumab 13rovalpituzumab tesirine 11amrubicin 11Specimen Handling 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Small Cell Lung Carcinoma × Fulvestrant × Clear all
NCT06257264 2026-05-11

A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

BeOne Medicines

Phase 1 Recruiting
258 enrolled
BreastGastrointestinalGenitourinaryGynecologicThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT04553133 2026-05-06

PF-07104091 as a Single Agent and in Combination Therapy

Pfizer

Phase 2 Active not recruiting
157 enrolled
BreastGynecologicThoracic

Breast Neoplasms, Ovarian Neoplasms, Small Cell Lung Carcinoma

NCT04247126 2023-10-27

A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors

Syros Pharmaceuticals

Phase 1 Completed
105 enrolled
BreastGastrointestinalThoracic

Breast Neoplasms, Pancreatic Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡